» Articles » PMID: 17576043

Postmenopausal HRT and Tibolone in Relation to Muscle Strength and Body Composition

Overview
Journal Maturitas
Specialty Geriatrics
Date 2007 Jun 20
PMID 17576043
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Sarcopenia, the loss of muscle mass with age, has a great impact on physical function, and especially in postmenopausal women, who experience a greater decline in muscle strength than do men of similar age. Conventional hormone replacement therapy (HRT) may diminish this loss of muscle strength and may even increase muscle strength. However, HRT is not currently promoted for this indication because of its negative side effects, which is why tibolone, a synthetic steroid with oestrogenic, progestogenic, and androgenic activity, may be an alternative option. The aim of this article was to review data on the effect of HRT and tibolone on muscle strength and body composition in postmenopausal women.

Methods: Medline, Pubmed, Embase, and Sumsearch were searched for articles on the effect of HRT and tibolone on muscle strength and body composition, using the Mesh terms hormone replacement therapy and clinical trial combined with muscle strength or body composition. Tibolone was added as search term with clinical trial and muscle strength or body composition.

Results: Three of five randomized controlled trials reported a significant positive effect of HRT on muscle strength but not on body composition. Tibolone significantly increased handgrip strength and isometric knee extension strength in one randomized placebo-controlled, double-blind trial and increased mean knee extensor strength in one cross-sectional study. Tibolone also increased the lean body mass and decreased the accumulation of body fat.

Conclusions: HRT and tibolone increase muscle strength. Unlike HRT, tibolone also increases lean body mass and significantly reduces the total body fat content. Further research is recommended to determine whether tibolone is a safe treatment for sarcopenia.

Citing Articles

Research progress on the correlation between estrogen and estrogen receptor on postmenopausal sarcopenia.

Zhang C, Feng X, Zhang X, Chen Y, Kong J, Lou Y Front Endocrinol (Lausanne). 2024; 15():1494972.

PMID: 39640884 PMC: 11617174. DOI: 10.3389/fendo.2024.1494972.


Potential application of anti-osteoporotic therapy to relieve sarcopenia in the elderly.

Li Y, Li X, Kong Z, Yin B, Lan Z, Li H Ann Med Surg (Lond). 2023; 85(12):6008-6012.

PMID: 38098566 PMC: 10718402. DOI: 10.1097/MS9.0000000000001352.


Effect of Tissue-Selective Estrogen Complex on Hip Structural Geometry in Postmenopausal Women: A 12-Month Study.

Kim B, Kim S, Lee D, Choi D Front Endocrinol (Lausanne). 2021; 12:649952.

PMID: 33776942 PMC: 7991728. DOI: 10.3389/fendo.2021.649952.


Flavonoids as Phytoestrogenic Components of Hops and Beer.

Tronina T, Poplonski J, Bartmanska A Molecules. 2020; 25(18).

PMID: 32937790 PMC: 7570471. DOI: 10.3390/molecules25184201.


Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO.

Vignozzi L, Malavolta N, Villa P, Mangili G, Migliaccio S, Lello S J Endocrinol Invest. 2018; 42(5):609-618.

PMID: 30456623 DOI: 10.1007/s40618-018-0978-x.